Current Filters

Showing 21 - 30 results of 3489

Tocilizumab (Actemra) (Last Updated: Feb 23, 2015)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Actemra
Manufacturer:
Hoffmann-La Roche Limited
Submission Type:
Initial
Indications:

Arthritis, Rheumatoid

Pasireotide diaspartate (Signifor) (Last Updated: Feb 27, 2014)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Signifor
Manufacturer:
Novartis Pharmaceuticals Inc.
Submission Type:
Initial
Indications:

Cushing’s Disease

Ranibizumab (Lucentis) (Last Updated: Feb 28, 2014)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Lucentis
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Submission Type:
Initial
Indications:

Choroidal neovascularisation, myopic

Umeclidinium/vilanterol (Anoro Ellipta) (Last Updated: Feb 26, 2014)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Anoro Ellipta
Manufacturer:
GlaxoSmithKline Inc.
Submission Type:
Initial
Indications:

Chronic Obstructive Pulmonary Disease

Canagliflozin (Invokana) (Last Updated: Feb 24, 2014)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Invokana
Manufacturer:
Janssen Inc.
Submission Type:
Initial
Indications:

Diabetes Mellitus, Type 2

Dolutegravir (Tivicay) (Last Updated: Oct 18, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Tivicay
Manufacturer:
ViiV Healthcare ULC
Submission Type:
Initial
Indications:

HIV infection

Golimumab (Simponi I.V.) (Last Updated: Sep 12, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Simponi I.V.
Manufacturer:
Janssen Inc.
Submission Type:
Initial
Indications:

Arthritis, Rheumatoid

Riociguat (Adempas) (Last Updated: Sep 30, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Adempas
Manufacturer:
Bayer Inc.
Submission Type:
Initial
Indications:

Pulmonary hypertension, chronic thromboembolic

Teriflunomide (Aubagio) (Last Updated: Aug 28, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Aubagio
Manufacturer:
Genzyme Canada, a Division of Sanofi Aventis Canada Inc.
Submission Type:
Initial
Indications:

Multiple Sclerosis, relapsing

Saxagliptin + Metformin (Komboglyze) (Last Updated: Aug 23, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Komboglyze
Manufacturer:
AstraZeneca Canada Inc.
Submission Type:
Initial
Indications:

Diabetes Mellitus, Type 2

Download results as CSV